AIM ImmunoTech Inc. (AIM) AI Stock Analysis

AIM ImmunoTech Inc. is an immuno-pharma company based in Ocala, Florida, specializing in therapeutics targeting various cancers, viral diseases, and immune-deficiency disorders. Its primary drug candidate is Ampligen, a macromolecular RNA-based therapeutic designed for chronic fatigue syndrome and being explored for multiple oncology indications, viral conditions, COVID-19, and post-COVID conditions. The company also offers Alferon N Injection, an injectable natural alpha interferon formulation used to treat genital warts. AIM ImmunoTech maintains research collaborations with organizations including UMN Pharma Inc., the Japanese National Institute of Infectious Diseases, Shionogi & Co., Ltd., Polysciences Inc., and the University of Cagliari.

Revenue dropped 48.2% in FY2025 to $88,000 from $170,000 in FY2024, down from $202,000 in FY2023. Over the five years from FY2020 to FY2025, revenue posted a compound annual growth rate of -11.6%. AIM ImmunoTech recorded net losses of -$19.1M in FY2021, -$19.4M in FY2022, -$29.0M in FY2023, -$17.3M in FY2024, and -$14.0M in FY2025. In FY2025, research and development expenses were $3.9M, operating margin was -11961.4%, and net margin was -15861.4%. In the trailing twelve months ended June 30, 2026, revenue stood at $95,000, while quarterly revenue growth was 4.0% year-over-year.

As of June 30, 2026, AIM ImmunoTech held $10.0M in cash and short-term investments and $3.9M in total debt, resulting in net cash of $6.0M. Total assets stood at $12.7M against shareholders' equity of $7.7M, with a current ratio of 2.11 and a debt-to-equity ratio of 0.51. In FY2025, free cash flow was -$11.3M and operating cash flow was -$11.0M. Capital expenditures were $378,000, while the company raised $8.3M from share issuances. Over five years, the share count increased 1197.9%.

AIM ImmunoTech trades at a price-to-sales multiple of 70.6x, compared to the median of 4.1x for its US-listed Healthcare peers. Its enterprise value stands at $2.2M with an EV-to-revenue multiple of 23.0x and EV-to-EBITDA of 0.5x, compared to the peer median EV-to-EBITDA of 12.0x. The company's forward P/E is 2.0x, below the peer group median of 17.3x, and its PEG ratio is 0.71. Over the past year, AIM shares fell 93.6%, while the S&P 500 (SPY) returned 16.8%.

Wall Street coverage consists of 1 Strong Buy and 1 Buy rating. The mean price target is $4.25, representing a 2428.3% premium over the last close of $0.17 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.78 on revenue of $74,000. For the following fiscal year, 1 analyst estimates revenue of $50,000 and EPS of -$0.37. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 16, 2026.

This page is an AI-written research summary of AIM ImmunoTech Inc. (AIM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AIM income statement, AIM balance sheet, AIM key metrics, AIM analyst forecast, AIM chart. See the AIM stock overview for the latest quote and news.